Lefright 10mg Tablet contains Leflunomide, an immunomodulatory agent used primarily in the management of rheumatoid arthritis and psoriatic arthritis. Leflunomide acts by inhibiting dihydroorotate dehydrogenase, a key enzyme involved in pyrimidine synthesis, thereby reducing the proliferation of activated lymphocytes responsible for inflammation and joint damage. This mechanism helps to alleviate symptoms such as joint pain, swelling, and stiffness, and may slow disease progression. Lefright is indicated for adult patients with active rheumatoid arthritis and psoriatic arthritis, particularly those who have had an inadequate response to or intolerance of other disease-modifying antirheumatic drugs (DMARDs). The recommended dosage is typically 10mg once daily, but dosing may be adjusted based on clinical response and tolerability. Common adverse effects include gastrointestinal disturbances, elevated liver enzymes, alopecia, and rash; therefore, regular monitoring of liver function tests and complete blood counts is advised during therapy. Lefright is contraindicated in pregnancy due to teratogenicity and should be used with caution in patients with hepatic impairment. Patients should be counseled on potential side effects and advised to report any signs of infection or unusual bleeding promptly. Lefright 10mg Tablet offers an effective option for controlling autoimmune joint inflammation and improving quality of life in affected individuals.